Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
A synthetic analog of growth hormone-releasing hormone (GHRH) that is FDA-approved for HIV-associated lipodystrophy. One of the few peptides with a clear FDA-approved indication, making it a useful reference point for the broader GHRH analog class.
A synthetic analog of the first 29 amino acids of growth hormone-releasing hormone (GHRH). One of the longest-studied GH-releasing peptides with a history of FDA approval for pediatric GH deficiency.
Binds to GHRH receptors on the pituitary gland, stimulating pulsatile GH release. Reduces visceral adipose tissue (VAT) through GH-mediated lipolysis. Maintains the natural pulsatile pattern of GH secretion, preserving feedback mechanisms.
Directly stimulates the pituitary gland to produce and release growth hormone through the natural GHRH pathway. Maintains the body's natural feedback mechanisms, reducing the risk of GH excess.
- HIV-associated lipodystrophy (FDA-approved)
- Visceral fat reduction
- Metabolic health improvement
- Growth hormone optimization (off-label)
- Cognitive function (emerging research in older adults)
- Growth hormone deficiency treatment
- Anti-aging protocols
- Improved sleep
- Body composition improvement
- Recovery enhancement
- Injection site reactions (common)
- Fluid retention and edema
- Arthralgia (joint pain)
- Potential glucose metabolism effects
- Contraindicated in active malignancy
- Injection site reactions (redness, swelling)
- Headaches
- Flushing
- Dizziness
- Generally well-tolerated in clinical studies
FDA-approved as Egrifta (tesamorelin for injection) in 2010 for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Also available through compounding pharmacies for off-label use with a physician prescription.
Previously FDA-approved as Geref for diagnostic use and pediatric GH deficiency (withdrawn from market for commercial reasons, not safety). Reclassified to Category 1 in February 2026 as part of the HHS announcement restoring compounding access. Not affected by the April 15, 2026 Category 2 removal action. Available through licensed 503A compounding pharmacies with a physician prescription.
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.